Corxel Pharmaceuticals completed a $287 million Series D to fund global development of CX‑11, an oral small‑molecule GLP‑1 receptor agonist for obesity and overweight patients. The financing will support the ongoing U.S. phase II study, a planned global phase II in type 2 diabetes, preparations for phase III and other cardiometabolic programs. Corxel said proceeds will accelerate CX‑11 toward registrational studies and broaden its clinical footprint in metabolic disease. The round underscores investor appetite for oral GLP‑1 approaches and competition in the obesity therapeutics market.